STOCKHOLM, May 28, 2024 /PRNewswire/ Calliditas Therapeutics AB , today announced the presentations of an additional efficacy analysis of Nefecon delayed release capsules)) as well as a.
The landmark FLOW study shows the benefits extend to kidney, cardiovascular, and mortality outcomes in high-risk patients with type 2 diabetes and CKD.
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label.
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1%.